![]() ![]() In BP CRUSH, treatment with AZOR was well tolerated, with no deaths or drug-related serious adverse events (AEs). "What makes these results so valuable is that there was no period of non-treatment before switching from one medication to another, so it allows us to see that patients responded safely and effectively to switching from monotherapy to AZOR."(1) Joel Neutel, MD, Director, Orange County Heart Institute and Research Center, Tustin, CA. "The results of this study may be of immediate practical use to physicians, as they show that switching patients from monotherapy to combination therapy was widely effective in helping patients better achieve blood pressure control," said Dr. Patients achieved a mean 24-hour ambulatory blood pressure reduction of 14.8/9.4 mm Hg from baseline (136.2/81.6 mm Hg) to Week 12.(1) ![]() The findings showed that patients treated with AZOR 10/40 mg experienced significant reductions in systolic blood pressure (SBP) of 20.3 mm Hg (mean baseline systolic blood pressure 154.0 mm Hg) and diastolic blood pressure (DBP) of 11.3 mm Hg (mean baseline diastolic blood pressure 92.3 mm Hg), P< 0.0001.(1)Ī total of 229 patients in BP CRUSH underwent pre-specified 24-hour ambulatory blood pressure measurement (ABPM). The prospective, open-label, multicenter, single-arm, dose titration Blood Pressure Cont rol in All S ubgroup s with Hypertension (BP CRUSH) sought to examine whether there would be a benefit of switching patients from monotherapy to AZOR without a washout period. Data were presented during the late breaker poster session of the American Society of Hypertension (ASH) annual meeting in New York. The study enrolled 999 patients unable to attain blood pressure control on monotherapy and switched to AZOR for a 20 week duration.(1) Uncontrolled hypertension was defined as mean systolic blood pressure (SBP) greater than or equal to 140 mm Hg and less than or equal to 180 mm Hg AND mean diastolic blood pressure (DBP) less than or equal to 110 mm Hg or mean SBP greater than or equal to 130 mm Hg and < 180 mm Hg AND mean DBP less than or equal to 110 mm Hg for patients with diabetes. A total of 71.3 percent of patients achieved a blood pressure goal of <140/90 mm Hg or 130/80 mm Hg for patients with diabetes during the first 12 weeks (60.6 percent at Week 12).(1) The primary endpoint of the study was the percentage of patients achieving seated systolic blood pressure goal of <140 mm Hg (<130 mm Hg patients with diabetes) cumulatively by Week 12. PARSIPPANY, N.J., May 3 /PRNewswire/ - Preliminary results from a dose titration study showed that treatment with the fixed-dose combination therapy AZOR® (amlodipine and olmesartan medoxomil) helped the majority (cumulative 75.8 percent) of hypertensive patients to reach systolic blood pressure goals of <140 mm Hg (<130 mm Hg for patients with diabetes) at any time point during the first 12 weeks and 66.1 percent non-cumulative at Week 12. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |